Previous close | 1.2600 |
Open | 1.2800 |
Bid | 1.3000 x 200 |
Ask | 1.3600 x 100 |
Day's range | 1.2800 - 1.4700 |
52-week range | 1.2100 - 7.9700 |
Volume | |
Avg. volume | 157,279 |
Market cap | 45.73M |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CLEARWATER, Fla., April 11, 2024--Apyx® Medical Corporation (NASDAQ:APYX) (the "Apyx Medical"; "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users’ Summit is taking place in Las Vegas from April 12-13, 2024.
CLEARWATER, Fla., March 21, 2024--Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024.
CLEARWATER, Fla., March 04, 2024--Apyx® Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st.